EGFR and non-small cell lung carcinoma: Given that lung cancer, particularly NSCLC with EGFR mutations, is the most common malignancy among thoracic medicine patients and is covered by the NHI system in Taiwan, thoracic medicine specialists are therefore especially attentive to NHI reimbursement issues.